Sumą deklaruoja pati organizacija Skaidrumo registre; institucijos jos netikrina.
Susitikimai pagal metus
20201202152025220264
Šaltinis: Europos Komisijos skelbiami susitikimai, sutapatinti pagal skaidrumo registro numerį. n = 12 susitikimų; x — metai pagal susitikimo datą, y — susitikimų skaičius.
Susitikimai su Europos Komisija
Skelbiami tik susitikimai su Komisijos nariais, jų kabinetais ir generaliniais direktoriais. Susitikimai žemesniu lygiu ir daugelis kontaktų Parlamente bei Taryboje į registrą nepatenka.
2025-09-10 · Simplification of administrative burdens in environmental legislation ↗ originalus šaltinis
Teva is committed to reducing its environmental footprint across operations and supply chains, while supporting resilient and sustainable healthcare systems. As a strategic partner to EU healthcare, Teva manufactures 96% of its European generic, biosimilar, and innovative medicines in 13 EU countries, contributing to Europes medicines security and industrial competitiveness. We welcome the Commissions goal of simplification of the environmental legislation. At the same time, it is essential to safeguard Europes medicines strategic autonomy and the competitiveness of its pharmaceutical industry. The simplification should address the impact of three key legislative frameworks. Urban Waste…
2023-04-24 · Review of the requirements for packaging and feasibility of measures to prevent packaging waste ↗ originalus šaltinis
At Teva Pharmaceuticals, our mission is to improve the lives of patients across the globe. In Europe, Teva is a strategic partner of healthcare systems, producing 96 % of its European generic, biosimilar and innovative portfolio in plants across 15 European countries. As a company focused on improving the health of patients, the environment has always been central to Teva. Our environmental commitments reflect how we minimise the impact of our operations and products on the planet. We welcome the derogations included by the Commission, however, we remain cautious about provisions on recyclability as it remains to be seen of its impact and how we must conform by 2035. Pharmaceutical…
Kokias ES temas nurodo sekanti
Public Health and access to medicines, Industrial and IP Policies, Pricing and Reimbursement Policies, Pharmaceutical legislation, European external trade agenda, global health, sustainability and green policies.
Paminėjimai spaudoje
Straipsniai, kuriuose organizacijos pavadinimas paminėtas pažodžiui IR kurie liečia teisę ar reguliavimą. Vien paminėjimas nereiškia, kad straipsnis yra apie lobizmą.
Teva faces scrutiny over efforts to curb generic competition Turkish regulators are investigating the drugmaker over its efforts to protect its drug from generic rivals—conduct that may sound…
…ic medicines.” While the Turkish regulator did not refer to a specific drug, Teva said in response that the investigation “relates to a legacy antitrust matter concerning Copaxone, similar to the…
Teva is increasingly highlighting its innovative drug bona fides these days, seeking to style itself as both a novel drug-producing biopharma and a generics powerhouse. Now, the company’s feet in…
At Teva, people are waiting to see the extent of the company's exposure to the various legal proceedings in which it is involved, and how much this will affect its limited ability to reschedule debt…